Pear Therapeutics Stock
Pear discovers, develops, and commercializes Prescription Digital Therapeutics to treat diseases with high unmet need.
About Pear Therapeutics Stock
Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better efficacy for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead product, reSET®, is an FDA-cleared 12-week interval prescription digital therapeutic for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. Pear’s product development pipeline includes reSET-O® for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (Thrive), combat posttraumatic stress disorder (reCALL), general anxiety disorder (reVIVE), pain, major depressive disorder, and insomnia, for which Pear intends to obtain FDA clearance.
Chief Science Officer
Co-Founder & Executive Vice President of Corporate Development
Head of Advisory Board
Founder & CEO
Co-Founder and Medical
Chief Product and Content Officer
VP of Market Access, Reimbursement & Government Affairs
Vice President of Commercialization
Vice President of Clinical Development